troglitazone has been researched along with Inborn Errors of Metabolism in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miles, PD | 1 |
| Barak, Y | 1 |
| Evans, RM | 1 |
| Olefsky, JM | 1 |
1 other study available for troglitazone and Inborn Errors of Metabolism
| Article | Year |
|---|---|
Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding.
Topics: Aging; Animals; Chromans; Dietary Fats; Heterozygote; Insulin Resistance; Metabolism, Inborn Errors; | 2003 |